SynthesisEuropean journal of clinical pharmacology2026
SGLT2 inhibitors and incretin-based therapies for metabolic dysfunction-associated steatohepatitis: a systematic review.
Artur Macedo Cruz et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.